DMT Efficacy vs Safety

Volume 5, Issue 5

DMT Efficacy vs Safety

In this issue:

The addition of newer, highly effective MS disease-modifying therapies provides clinicians unprecedented flexibility in individualizing treatment. But along with increased efficacy come increased safety concerns. What do clinicians need to know to ensure the best possible care for their patients? What does the evidence say?

Those are some of the questions addressed by Drs. Le Hua and Areeba Siddiqui from the Cleveland Clinic’s Lou Ruvo Center for Brain Health in this issue of eMultipleSclerosis Review.

Learning objectives:

Discuss the role of alternate dosing regimens for disease-modifying therapies.
Identify therapeutic agents associated with lymphopenia and related risks of infection.

Authors:

Le H. Hua, MD

Professor of Neurology
Director, Multiple Sclerosis Section
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, NV

Areeba Siddiqui, MD

Fellow, Multiple Sclerosis and Neuroimmunology
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, NV

Guest Faculty Disclosures

Dr. Hua has disclosed that she has served as an advisor for EMD Serono and Novartis AG and received grant/research support from Biogen Idec. Dr. Siddiqui has indicated that he has no financial interests in or relationships with a commercial entity. 

Unlabeled/Unapproved Uses

Dr. Hua and Dr. Siddiqui have indicated that they will reference the off-label intervals for natalizumab and B cell monoclonal antibodies; S1P1 modulators may be discussed as risk-mitigation strategies.

Program Directors:

Pavan Bhargava, MBBS, MD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Lisa Fox, PA-C, MPAS

Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Guest Faculty Disclosures:

Unlabeled/Unapproved Uses:

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: August 2, 2023
Expiration date: August 1, 2025

Start Issue